AVRO News and Press, AVROBIO Inc. From 07/16/19

Gainers:  Immuron (NASDAQ: IMRN ) +81% . Blue Apron Holdings (NYSE: APRN ) +49% . Moxian (NASDAQ: MOXC ) +35% . GAIN Capital Holdings (NYSE: GCAP ) +32% . Lonestar Resources (NASDAQ: LONE ) +19% . AVROBIO (NASDAQ: AVRO ) +17% . Dolphin Entertainment (NASDAQ: DLPN ) +16% . Bio-P...

Gainers:  Capricor Therapeutics (NASDAQ: CAPR ) +148% . Carolina Trust BancShares (NASDAQ: CART ) +30% . SSLJ.com Limited (YGTY) +29% . Chicken Soup for the Soul Entertainment (NASDAQ: CSSE ) +22% . AVROBIO (NASDAQ: AVRO ) +22% . Mereo BioPharma Group (NASDAQ: MREO ) +21% . Amer...

Thinly traded AVROBIO ( AVRO +7.9% ) is up on increased volume in early trade following its announcement of additional positive data and the first kidney biopsy results from its two ongoing clinical trials evaluating gene therapy candidate AVR-RD-01 in patients with an inherited disorder...

– 87% reduction in average number of Gb3 inclusions in first kidney biopsy taken one year post-treatment, the primary efficacy endpoint in the Phase 2 trial – Plasma lyso-Gb3 consistently reduced 33% to 41% below baseline enzyme replacement therapy (ERT) levels in the first ...

AVROBIO (NASDAQ: AVRO ): Q1 GAAP EPS of -$0.72 in-line. More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Regulatory clearances achieved that enable integration of the plato™ platform into Fabry FAB-201 and Gaucher GAU-201 clinical trials in the second half of 2019 IND for AVR-RD-01 for the treatment of Fabry disease cleared by the FDA; AVROBIO plans to open U.S. clinical trial site...

Krystal Biotech (KRYS) - The company announced presentations of clinical data for KB103 to treat DEB (dystrophic epidermolysis bullosa) and preclinical data on KB105 for the treatment of autosomal recessive congenital ichthyosis (ARCI) and KB104 for the treatment of Netherton syndrome at t...

The FDA has cleared AVROBIO's (NASDAQ: AVRO ) IND application for AVR-RD-01, its gene therapy candidate for the treatment of Fabry disease. More news on: AVROBIO, Inc., Healthcare stocks news, Read more ...

The plato™ platform represents a significant advance towards a commercial-stage gene therapy solution designed to treat thousands of patients AVROBIO to incorporate U.S. clinical sites into its ongoing global FAB-201 Phase 2 clinical trial in Fabry disease AVROBIO, Inc...

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the participation of its senior management in sessions at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). These include sessions on a...